Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.

Biagio Ricciuti,Kathryn Cecilia Arbour,Jessica J. Lin,Natalie I. Vokes,Amir Vajdi Hoojghan,Yvonne Y. Li,Andrew D. Cherniack,Gonzalo Recondo,Giuseppe Lamberti,Deepti Venkatraman,Hira Rizvi,Jacklynn V. Egger,Andrew J. Plodkowski,S. Khosrowjerdi,Subba R. Digumarthy,Mizuki Nishino,Lynette M. Sholl,Justin F. Gainor,Matthew D. Hellmann,Mark M. Awad

Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.

2020

e15113Background: STK11 mutations (STK11m) have been associated with resistance to ICI in KRAS-mutant (KRASm) NSCLC. Whether STK11m status also impacts clinical outcomes to ICI in KRAS wild-type (w...

Keywords:

STK11
Pathology
non-small cell lung cancer (NSCLC)
Cancer research
kras mutation
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations